Panacea Life Sciences Holdings, Inc. Announces CBD/CBG Clinical Trial Findings for the Management of Irritable Bowel Symptoms
20 juil. 2023 09h15 HE
|
Panacea Life Sciences Holdings, Inc.
GOLDEN, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) (“Panacea” or the “Company”), a plant-based natural health and wellness company, today announced it...
Global Constipation Treatment Market Report 2023-2030 - Lucrative Opportunities in China as the Chinese Market is Forecast to Grow at 9% CAGR
23 juin 2023 04h23 HE
|
Research and Markets
Dublin, June 23, 2023 (GLOBE NEWSWIRE) -- The "Constipation Treatment: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Constipation Treatment...
Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).
17 avr. 2023 07h47 HE
|
Biomerica, Inc.
Gastro Health is a leading gastroenterology group with over 380 GI physicians in the United StatesClinical study results show patients who eliminated foods as determined by the inFoods® IBS test...
Biomerica InFoods® IBS Data Presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting
02 nov. 2022 08h19 HE
|
Biomerica, Inc.
ACG Presidential Award Received for the InFoods® IBS Data Presented at the American College of Gastroenterology (ACG) Annual Scientific MeetingThe Presented Clinical Study Data Showed InFoods® IBS...
metaMe Health partners with Launchit Ventures to market Regulora, an FDA-cleared Prescription Digital Therapeutic for adults with IBS, in Canada
29 sept. 2022 09h00 HE
|
metaMe Health, Inc.
HAMILTON, Ontario and CHICAGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Launchit Ventures, Inc., a HealthTech solutions provider and global commercialization partner developing new technology-led business...
Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer
30 août 2022 08h19 HE
|
Biomerica, Inc.
InFoods® IBS commercial launch and revenues expected before the close of calendar year 2022Mr. Carlson is an accomplished and performance-driven Commercial and Corporate Strategy and Development...
Biomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues to $7.6 million vs. Q3 Fiscal 2021
14 avr. 2022 08h37 HE
|
Biomerica, Inc.
Q3 Net loss per share of $0.01 vs. a net loss of $0.18 per share from same period last year InFoods® IBS diagnostic-guided therapy clinical trial results demonstrated statistically significant...
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome
08 févr. 2022 06h39 HE
|
Biomerica, Inc.
InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of IBS...
Jasco Introduces New JascoPro Brand at International Builder Show
07 févr. 2022 08h00 HE
|
Jasco
OKLAHOMA CITY, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Connected home leader, Jasco, today unveils the new JascoPro Series brand at the International Builder Show in Orlando. Exclusive to the professional...
Scientists and Nutritionists Collaborate on a New, Powerful Gut Health Dietary Supplement
04 févr. 2022 09h00 HE
|
Synesis Nutrition, Inc.
CAMBRIDGE, Wis., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Wisconsin-based nutrition and food chemistry experts at Synesis Nutrition, Inc. have collaborated on the development of a unique new product that...